Study	Reason for exclusion
Blader 2009	Adjunctive divalproex versus placebo for children with ADHD and aggression refractory to stimulant monotherapy. Divalproex is considered to be a mood stabiliser. Ineligible intervention.
Blader 2013	Open titration and optimisation of stimulant monotherapy in 160 children. Ineligible study design (not randomised) and ineligible intervention.
Buitelaar 2000	Open‐label study of risperidone treatment in 26 hospitalised children and youths with borderline or sub‐average IQs with mixed diagnoses and aggressive behaviour. Ineligible study design (not randomised).
Croonenberghs 2005	1‐year, multi‐site, open‐label study looking at safety and effectiveness of risperidone in 504 children and youths aged 5 to 14 with disruptive behaviour disorders and below average IQs. Ineligible study design (not randomised).
Findling 2004	48‐week open‐label study of risperidone in 107 children aged 5 to 12 with severe disruptive behaviour disorders and below average IQs. Ineligible study design (not randomised).
Findling 2006	8‐week pilot, open‐label, outpatient trial of quetiapine in 17 aggressive children with conduct disorder aged 6 to 12 years old. Ineligible study design (not randomised).
Haas 2008	1‐year, open‐label, safety extension study in 232 children with disruptive behaviour disorders treated with risperidone. Ineligible study design (not randomised).
Handen 2006	Open‐label trial of olanzapine in 16 youths with sub‐average IQ and disruptive behaviour disorders. Ineligible study design (not randomised).
Holzer 2013	Open‐label atomoxetine and olanzapine in ADHD with comorbid disruptive behaviour disorder in children and adolescents. Ineligible study design (not randomised).
ISRCTN95609637	Study on hold since 2013. Relapse prevention in children and adolescents with Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM‐IV) Conduct Disorder treated with risperidone: a randomised double‐blind, placebo‐controlled, discontinuation study (www.isrctn.com/ISRCTN95609637). Discontinued study/no data available.
Kuperman 2010	Open‐label trial of aripiprazole in the treatment of conduct disorders in adolescents. Ineligible study design (not randomised).
Masi 2006	A retrospective chart review of olanzapine treatment in adolescents with conduct disorder. Ineligible study design (not randomised).
NCT00279409	Treatment of Children With ADHD Who do Not Fully Respond to Stimulants (TREAT). Active comparator (also called the "combination arm") consists of parent training plus continued treatment on a stimulant, plus augmentation with aripiprazole. Placebo comparator (also called the "simple treatment" arm) will consist of parent training plus continued treatment on a stimulant plus a placebo matching aripiprazole. Study was terminated due to slow rate of recruitment. Discontinued study/no data available. ClinicalTrials.gov Identifier: NCT00279409.
NCT00550147	An open‐label study of quetiapine added to OROS methylphenidate in the treatment of ADHD and aggressive behaviour. Ineligible study design (not randomised).
Reyes 2006b	Open‐label study over a cumulative period of 3 years, looking at safety and tolerability of risperidone in 35 children with disruptive behaviour disorders and borderline and sub‐average IQs. Ineligible study design (not randomised).
Safavi 2016	Ineligible study design (single‐blind design).
Soderstrom 2002	A clinical case series of 6 extremely aggressive youths treated with olanzapine. Ineligible study design (not randomised).
Teixeira 2013a	Open, naturalistic study of clozapine in 7 boys with severe conduct disorder over 26 weeks. Ineligible study design (not randomised).
Tramontina 2009	Response to treatment with aripiprazole in children and adolescents with bipolar disorder and comorbid ADHD. Ineligible study design (not randomised).
Turgay 2002	48‐week open‐label study of risperidone for the treatment of disruptive behaviour disorders in 77 children with sub‐average IQs. Ineligible study design (not randomised).
Tyrer 2008	RCT in adults of risperidone, haloperidol and placebo in the treatment of aggressive challenging behaviour in adult patients with intellectual disability. Ineligible population (adults).

ADHD: attention deficit hyperactivity disorder.
 IQ: intelligence quotient.
 RCT: randomised controlled trial.